Compass Pathways PLC (CMPS) Stock AnalysisCMPSStock AnalysisCompass Pathways PLC

Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Compass Pathways PLC is a good buy right now, with a current price of $13.73 and a significant year-to-date change of +109.62%. The stock has shown strong momentum, with a 20-day change of +20.97% and a solid cash position of $433 million, which supports operations through 2028. However, the main risk is the negative EPS of -1.88 reported in Q2 2026, indicating ongoing losses.